ORPHA:300865
Primary cutaneous anaplastic large cell lymphoma
Also known as: Primary C-ALCL · Regressive atypical histiocytosis
Publications
1,051
Trials
9
Interventional, condition-specific
Researchers
1,069
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare T-cell non-Hodgkin lymphoma that affects the skin and generally shows no extracutaneous involvement at presentation. It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders along with lymphomatoid papulosis with which it shares overlapping clinical and histopathologic features.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017598
- MeSH:D054446
- UMLS:C1301362
- NCIT:C6860
Additional Mondo synonyms (10)
ALCL, cutaneous · C-ALCL · anaplastic large-cell lymphoma, primary cutaneous type · primary C-ALCL · primary anaplastic large cell lymphoma of skin · primary anaplastic large cell lymphoma of the skin · primary cutaneous CD30 Positive anaplastic large cell lymphoma · primary cutaneous CD30+ ALCL · primary cutaneous CD30+ anaplastic large cell lymphoma · regressive atypical histiocytosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,051 matched papers (665 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,051
1,051 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,051 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
665 in the last 10 years · low confidence
Phrase hits: 1,050 · MeSH hits: 1
Who's working on it?
1,069
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Melchers RC6 papers · 2024
Department of Dermatology, Leiden University Medical Center, the Netherlands.
Papers in Europe PMC - 02Li S5 papers · 2026
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Papers in Europe PMC - 03Quint KD5 papers · 2022
Department of Dermatology, Leiden University Medical Center, the Netherlands.
Papers in Europe PMC - 04Vermeer MH5 papers · 2024
Department of Dermatology, Leiden University Medical Center, the Netherlands.
Papers in Europe PMC - 05Chen H4 papers · 2025
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
Papers in Europe PMC - 06Kempf W4 papers · 2025
Kempf und Pfaltz Histologische Diagnostik, 8050 Zürich, Switzerland.
Papers in Europe PMC - 07Quaglino P4 papers · 2024
Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
Papers in Europe PMC - 08Willemze R4 papers · 2022
Department of Dermatology, Leiden University Medical Center, the Netherlands.
Papers in Europe PMC - 09Zhang C4 papers · 2025
Pathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanging, China, zccjy0614@163.com.
Papers in Europe PMC - 10Zhang Y4 papers · 2026
Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 176 trials are registered for anaplastic large cell lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
low confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07717580·NOT YET RECRUITING·Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
Not reviewed·Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides · Primary Cutaneous Anaplastic Large Cell Lymphoma·Matched via name phrase
Broader category: anaplastic large cell lymphoma
176
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06561048·RECRUITING·Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Not reviewed·Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified · Angioimmunoblastic T-cell Lymphoma · Follicular T-Cell Lymphoma · Nodal Peripheral T-Cell Lymphoma With TFH Phenotype·Matched via name phrase
- NCT07001384·RECRUITING·A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Not reviewed·Conditions: Anaplastic Lymphoma Kinase · Anaplastic Large Cell Lymphoma·Matched via name phrase
- NCT06494371·RECRUITING·A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Not reviewed·Conditions: Hodgkin's Lymphoma · Anaplastic Large Cell Lymphoma·Matched via name phrase
- NCT03017820·RECRUITING·A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Not reviewed·Conditions: B-Cell Non-Hodgkin Lymphoma · Histiocytic and Dendritic Cell Neoplasm · Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome·Matched via name phrase
- NCT05770037·RECRUITING·DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Not reviewed·Conditions: Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type·Matched via name phrase
- NCT05544968·RECRUITING·Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Not reviewed·Conditions: Hodgkin Disease · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30+ Anaplastic Large Cell Lymphoma · CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma·Matched via name phrase
- NCT04925609·RECRUITING·Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Not reviewed·Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive · Inflammatory Myofibroblastic Tumor · Other Solid Tumor·Matched via name phrase
- NCT06724237·RECRUITING·Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Not reviewed·Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative · Follicular Helper T-Cell Lymphoma · Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type · Peripheral T-Cell Lymphoma, Not Otherwise Specified·Matched via name phrase
- NCT07013565·RECRUITING·Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Not reviewed·Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive·Matched via name phrase
- NCT04195633·RECRUITING·Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Not reviewed·Conditions: Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult Diffuse Large Cell Lymphoma·Matched via name phrase
- NCT07729397·NOT YET RECRUITING·Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Not reviewed·Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) · Hodgkin Lymphoma · Peripheral T-cell Lymphoma (PTCL) · Anaplastic Large Cell Lymphoma, ALK-Positive·Matched via name phrase
- NCT07055477·RECRUITING·A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Not reviewed·Conditions: Relapsed and/or Refractory Mature T Cell Malignancy · Peripheral T-Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Anaplastic Large Cell Lymphoma·Matched via name phrase
- NCT07691450·NOT YET RECRUITING·Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
Not reviewed·Conditions: Recurrent Anaplastic Large Cell Lymphoma · Recurrent Enteropathy-Associated T-Cell Lymphoma · Recurrent Follicular Helper T-Cell Lymphoma · Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type·Matched via name phrase
- NCT06508463·RECRUITING·Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Not reviewed·Conditions: Peripheral T Cell Lymphoma · Relapsed Peripheral T-Cell Lymphoma · Peripheral T-Cell Lymphoma, Not Otherwise Specified · Anaplastic Large Cell Lymphoma·Matched via name phrase
- NCT07535762·NOT YET RECRUITING·Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Not reviewed·Conditions: Peripheral T-Cell Lymphoma (PTCL NOS) · Nodal T-follicular Helper Cell Lymphoma · Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05978141·RECRUITING·A Registry for People With T-cell Lymphoma
Not reviewed·Conditions: T-cell Lymphoma · NK-Cell Lymphoma · T-cell Prolymphocytic Leukemia · T-cell Large Granular Lymphocytic Leukemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Primary cutaneous anaplastic large cell lymphoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary cutaneous anaplastic large cell lymphoma" OR "Primary C-ALCL" OR "Regressive atypical histiocytosis" OR "ALCL, cutaneous" OR "C-ALCL" OR "anaplastic large-cell lymphoma, primary cutaneous type" OR "primary anaplastic large cell lymphoma of skin" OR "primary anaplastic large cell lymphoma of the skin" OR "primary cutaneous CD30 Positive anaplastic large cell lymphoma" OR "primary cutaneous CD30+ ALCL" OR "primary cutaneous CD30+ anaplastic large cell lymphoma"
MeSH descriptor terms unioned into the query: Lymphoma, Primary Cutaneous Anaplastic Large Cell
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary cutaneous anaplastic large cell lymphoma" OR "Primary C-ALCL" OR "Regressive atypical histiocytosis" OR "ALCL, cutaneous" OR "C-ALCL" OR "anaplastic large-cell lymphoma, primary cutaneous type" OR "primary anaplastic large cell lymphoma of skin" OR "primary anaplastic large cell lymphoma of the skin" OR "primary cutaneous CD30 Positive anaplastic large cell lymphoma" OR "primary cutaneous CD30+ ALCL" OR "primary cutaneous CD30+ anaplastic large cell lymphoma" OR "Lymphoma, Primary Cutaneous Anaplastic Large Cell"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"anaplastic large cell lymphoma"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1051) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T12:44:37.031Z
